Technology news and discussion on TalkFuse.
Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
Major pharmaceutical companies say AI is speeding up early drug discovery, with some reporting that it has halved the time needed to design molecules and advance them towards clinical testing. The claims suggest AI could reduce delays and costs in a process where most drug candidates fail, while Anthropic’s push into drug discovery raises the prospect of competition and partnerships with established firms.
Sanofi says an AI-supported approach saved at least a year in developing an asthma treatment; Novo Nordisk reports reducing design-and-test cycles from about eight to three, and cutting each cycle from eight weeks to four. In March, researchers counted 129 AI-related drug candidates across 69 companies, up from roughly 117 eight months earlier, but most remain at an early stage. Scientists caution that AI has yet to show it improves clinical success or speeds approvals, which still depend on lengthy trials and regulatory review.
In short
- Pharma firms say AI is speeding early drug discovery.
- Novo Nordisk cut molecule testing cycles from eight to three.
- Most AI drug candidates remain in early development.
AI Health Medicine Research Science Technology World